We have sales. We have cash. We have a product. We have good management that has hit targets. Of which, has invested heavily into the company.
Asthma is a huge market that isn't speculative in nature. This isn't some roll the dice cancer stock, neither is it a mining stock turned weed. All ADR needs to do is limit cash burn, sell the product and grow. All we need to do is give it time.
Adherium receives US FDA 510k OTC clearance, page-28
Add ADR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.65M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27930 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 1338 | 1 |
View Market Depth
| Last trade - 16.27pm 10/07/2024 (20 minute delay) ? |
| ADR (ASX) Chart |
Day chart unavailable